Close

Takeda announces availability of type 2 diabetes drugs in US

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.
Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider.

Related stories

Modernizing Pharmaceutical Research through Innovation

The trajectory of drug discovery and development is intrinsically...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

Thermo Fisher Scientific’s KingFisher Compact System Automates Sample Purification

Sample purification is an important step in research workflows...
- Advertisement -

Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US.

The FDA approved medications are indicated as an addition to diet and exercise for the treatment of type 2 diabetes.

Takeda Pharmaceuticals USA diabetes and obesity marketing senior director Jennifer Greeby said, “The availability of NESINA, KAZANO and OSENI marks an important milestone in Takeda’s commitment to patients living with type 2 diabetes, and provides new options for physicians.”

The dipeptidyl peptidase-4 inhibitor (DPP-4i), NESINA, is designed to slow the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).

Combination of alogliptin with metformin HCl, KAZANO, is an anti-diabetes medication formulated in a single tablet in addition to single tablet regeime OSENI that combines alogliptin with the thiazolidinedione (TZD) pioglitazone.

 

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Modernizing Pharmaceutical Research through Innovation

The trajectory of drug discovery and development is intrinsically...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

Thermo Fisher Scientific’s KingFisher Compact System Automates Sample Purification

Sample purification is an important step in research workflows...

Role of Antibody Evaluation in Research and Thermo Fisher’s Free Sample Programme

Selecting the right antibody is an important consideration for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »